Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;23(5):225-233.
doi: 10.1007/s11910-023-01265-3. Epub 2023 Apr 15.

Therapies for IDH-Mutant Gliomas

Ruham Alshiekh Nasany  1 , Macarena Ines de la Fuente  2
Affiliations
Review

Therapies for IDH-Mutant Gliomas

Ruham Alshiekh Nasany et al. Curr Neurol Neurosci Rep. 2023 May.

Abstract

Purpose of review: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct type of primary brain tumors with unique characteristics, behavior, and disease outcomes. This article provides a review of standard of care treatment options and innovative, therapeutic approaches that are currently under investigation for these tumors.

Recent findings: Extensive pre-clinical data and a variety of clinical studies support targeting IDH mutations in glioma using different mechanisms, which include direct inhibition and immunotherapies that target metabolic and epigenomic vulnerabilities caused by these mutations. IDH mutations have been recognized as an oncogenic driver in gliomas for more than a decade and as a positive prognostic factor influencing the research for new therapeutic methods including IDH inhibitors, DNA repair inhibitors, and immunotherapy.

Keywords: Astrocytoma; Glioma; IDH inhibitors; IDH mutations; Immunotherapy; Oligodendroglioma.

PubMed Disclaimer

Conflict of interest statement

RAN has no disclosures. MID reports participation as an advisory board member for Agios Pharmaceuticals and Forma Therapeutics.

Figures

Fig. 1
Fig. 1
The IDH enzymes family and their role in cell metabolism as well as the effect of IDH mutations on the Krebs cycle and the accumulation of D-2-HG
Fig. 2
Fig. 2
The 2021 WHO classification of adult-type diffuse gliomas
See this image and copyright information in PMC

References

    1. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432–446. doi: 10.1016/S0140-6736(18)30990-5. - DOI - PubMed
    1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93–108. doi: 10.1007/s00401-005-0991-y. - DOI - PubMed
    1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. doi: 10.1126/science.1164382. - DOI - PMC - PubMed
    1. Kayabolen A, Yilmaz E, Bagci-Onder T. IDH mutations in glioma: double-edged sword in clinical applications? Biomedicines. 2021;9(7):799. doi: 10.3390/biomedicines9070799. - DOI - PMC - PubMed
    1. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–1153. doi: 10.2353/ajpath.2009.080958. - DOI - PMC - PubMed

Substances